Volume 29, Number 11—November 2023
CME ACTIVITY - Synopsis
Campylobacter fetus Invasive Infections and Risks for Death, France, 2000–2021
Souheil Zayet
, Timothée Klopfenstein, Vincent Gendrin, Jean-baptiste Vuillemenot, Julie Plantin, Lynda Toko, Nour Sreiri, and Pierre-Yves Royer
, Timothée Klopfenstein, Vincent Gendrin, Jean-baptiste Vuillemenot, Julie Plantin, Lynda Toko, Nour Sreiri, and Pierre-Yves Royer
Table 3
Antimicrobial resistance of Campylobacter fetus strains isolated from patients with and without bacteremia, Nord Franche-Comté Hospital, Trévenans, France, 2000–2021*
| Antimicrobial tested | All patients, no. (%), n = 33 | Patients with no C. fetus bacteremia, no. (%), n = 12 |
Patients with C. fetus bacteremia, no. (%), n = 21 |
p value |
|---|---|---|---|---|
| Amoxicillin† | 3/28 (10.7) | 1/8 (12) | 2/20 (10) | 0.3 |
| Amoxicillin–clavulanic acid | 0/28 | 0/8 | 0/20 | |
| Imipenem | 0/28 | 0/8 | 0/20 | |
| Gentamicin | 0/27 | 0/8 | 0/19 | |
| Azithromycin | 2/29 (6.9) | 0/9 | 2/20 (10) | >0.9 |
| Fluoroquinolones: ofloxacin and ciprofloxacin‡ | 8/27 (30) | 2/9 (22) | 6/18 (33) | 0.7 |
| Doxycycline | 7/29 (24) | 1/9 (11) | 6/20 (30) | 0.4 |
*Values are no. resistant/no. tested (%) except as indicated. Blank cells for p values indicate no p value was calculated. †Susceptibility to amoxicillin was intermediate (susceptible with high doses) for 2 strains. ‡Susceptibility to ofloxacin and ciprofloxacin was the same for all strains.
Page created: September 06, 2023
Page updated: October 17, 2023
Page reviewed: October 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.